Brown Financial Advisors Purchases 3,839 Shares of DexCom, Inc. (NASDAQ:DXCM)

Brown Financial Advisors lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 35.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 14,632 shares of the medical device company’s stock after purchasing an additional 3,839 shares during the period. Brown Financial Advisors’ holdings in DexCom were worth $1,138,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of DXCM. Jennison Associates LLC lifted its holdings in DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares during the period. Congress Asset Management Co. raised its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD purchased a new stake in DexCom in the fourth quarter worth $96,507,000. Westfield Capital Management Co. LP boosted its holdings in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after purchasing an additional 739,000 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research analyst reports. Citigroup lifted their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Wells Fargo & Company upped their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Canaccord Genuity Group raised their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Finally, Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.06.

DexCom Stock Up 2.2 %

NASDAQ:DXCM opened at $90.75 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $35.46 billion, a P/E ratio of 63.46, a P/E/G ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a 50-day simple moving average of $83.50 and a two-hundred day simple moving average of $76.11.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock worth $3,309,794 over the last quarter. 0.30% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.